🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: PT003 MDI

Found 22 matching trials

PT003 MDI Dose Confirmation Study

PHASE2

The primary objective of this study is to demonstrate efficacy of PT003 MDI...

Status

Completed

Location

Pearl Investigative Site

Start Date

2011-06

Trial ID

NCT01349816

Treatments Being Tested

PT003 PT001 PT005

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE2

The primary objective of this study is to assess the efficacy of Glycopyrro...

Status

Completed

Location

Pearl Investigative Site

Start Date

2012-04

Trial ID

NCT01587079

Treatments Being Tested

PT003 PT001 PT005 Tiotropium inhalation powder

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

PHASE3

This is a randomized, double-blind, multi-center, parallel-group study to a...

Status

Completed

Location

Research Site

Start Date

2015-06-30

Trial ID

NCT02465567

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BGF MDI 160/14.4/9.6 μg BFF MDI 320/9.6 μg

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to evaluate, after 1 week of dosing, the effic...

Status

Completed

Location

Clinical Research of West Florida, Inc.

Start Date

2010-03

Trial ID

NCT01085045

Treatments Being Tested

PT003 MDI PT005 MDI Placebo MDI Tiotropium bromide 18 μg (Spiriva Handihaler®)Formoterol Fumarate 12 μg (Foradil® Aerolizer®)PT001 MDI

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

PHASE3

A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-C...

Status

Completed

Location

Research Site

Start Date

2016-08-09

Trial ID

NCT03262012

Treatments Being Tested

BGF MDI (PT010)GFF MDI (PT003)BFF MDI (PT009)Symbicort® Turbohaler® Inhalation Powder

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

PHASE3

Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-cente...

Status

Completed

Location

Multiple Locations

Start Date

2015-02-01

Trial ID

NCT02347085

Treatments Being Tested

GFF MDI (PT003)Placebo MDI

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

PHASE1

A study to assess the pharmacokinetics and safety of two doses of PT010 and...

Status

Completed

Location

Research Site

Start Date

2017-04-17

Trial ID

NCT03075267

Treatments Being Tested

PT010 (BGF MDI) 320/14.4/9.6 µg PT010 (BGF MDI) 160/14.4/9.6 µg PT003 (GFF MDI) 14.4/9.6 µg

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

PHASE3

Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Ba...

Status

Completed

Location

Research Site

Start Date

2015-12-23

Trial ID

NCT02643082

Treatments Being Tested

GFF MDI (PT003) 14.4/9.6μg Placebo MDI

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

PHASE3

Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-...

Status

Completed

Location

Multiple Locations

Start Date

2015-02-01

Trial ID

NCT02347072

Treatments Being Tested

GFF MDI (PT003)Placebo MDI Spiriva® Respimat® (Tiotropium Bromide)

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

PHASE3

This is a multi-center, randomized, double-blind, parallel group, chronic d...

Status

Completed

Location

Pearl Investigative Site

Start Date

2013-11

Trial ID

NCT01970878

Treatments Being Tested

GFF MDI (PT 003)GP MDI (PT001)FF MDI (PT005)Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)

Previous Next